Synthetic cannabidiol - INSYS Therapeutics

Drug Profile

Synthetic cannabidiol - INSYS Therapeutics

Alternative Names: Pharmaceutical cannabidiol (CBD) - INSYS Therapeutics

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Developer California Pacific Medical Center; INSYS Therapeutics, Inc; The University of Montreal Hospital Research Center; University of Chicago
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Dravet syndrome; Lennox-Gastaut syndrome; Infantile spasms; Glioblastoma; Schizophrenia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome; Drug abuse; Lennox-Gastaut syndrome
  • Phase II Infantile spasms
  • Phase I/II Epilepsy; Pain
  • Preclinical Glioblastoma; Peripheral nervous system diseases

Most Recent Events

  • 10 Oct 2017 Synthetic cannabidiol is still in phase I/II trials for Epilepsy (In adolescents, In children, In infants) in USA (INSYS Therapeutics pipeline, October 2017)
  • 20 Jun 2017 MultiCare Health System Research Institute initiates an expanded access for Seizures (In children, Adjunctive treatment) (NCT03196934)
  • 01 Mar 2017 INSYS Pharma completes a phase III trial in Drug abuse (In volunteers) in USA (unspecified route) (NCT02902081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top